AstraZeneca Surpasses Q3 Expectations with Robust Revenue Growth ...Middle East

Devdiscourse - Opinion
AstraZeneca Surpasses Q3 Expectations with Robust Revenue Growth
AstraZeneca has delivered an impressive financial performance in the third quarter of 2024, surpassing market expectations. The pharmaceutical giant reported a core EPS of $2.08, eclipsing the IBES estimate of $2.01, and total revenue of $13,565 million, which exceeded the forecasted $13,046 million.

Hence then, the article about astrazeneca surpasses q3 expectations with robust revenue growth was published today ( ) and is available on Devdiscourse ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AstraZeneca Surpasses Q3 Expectations with Robust Revenue Growth )

Apple Storegoogle play

Last updated :

Also on site :



Latest News